ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00477425
Recruitment Status : Withdrawn
First Posted : May 23, 2007
Last Update Posted : May 15, 2017
Sponsor:
Information provided by:
Genentech, Inc.

Brief Summary:
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Condition or disease
Carcinoma

Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Actual Study Start Date : June 2007
Actual Primary Completion Date : June 2007
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form
  • Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

  • Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • Congenital long QT syndrome
  • Family history of long QT syndrome
  • Clinically significant bradycardia (defined as < 50 beats/minute)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00477425


Sponsors and Collaborators
Genentech, Inc.
Investigators
Study Director: Jane Huang, M.D. Genentech, Inc.

ClinicalTrials.gov Identifier: NCT00477425     History of Changes
Other Study ID Numbers: AVF4223g
First Posted: May 23, 2007    Key Record Dates
Last Update Posted: May 15, 2017
Last Verified: May 2017

Keywords provided by Genentech, Inc.:
Avastin

Additional relevant MeSH terms:
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents